A phase 2 study of olaparib in IDH1 and IDH2 mutant advanced chondrosarcomas and other solid tumors.
Costa P, Pilat M, Rodon Ahnert J, Burgess M, Tinoco G, Close J, Groisberg R, Subbiah V, Powers B, Haddox C, Grilley-Olson J, Keedy V, Li J, Ivy S, Patel A, Shapiro G, Ishizuka J, Schalper K, LoRusso P. A phase 2 study of olaparib in IDH1 and IDH2 mutant advanced chondrosarcomas and other solid tumors. Journal Of Clinical Oncology 2025, 43: 3087-3087. DOI: 10.1200/jco.2025.43.16_suppl.3087.Peer-Reviewed Original ResearchProgression-free survivalSolid tumorsOverall survivalClinical benefitOpen-label phase II clinical trialSolid tumors refractory to standard treatmentMedian progression-free survivalRefractory to standard treatmentIDH mutant tumorsPhase II clinical trialBRCA-mutated cancersEfficacy of olaparibPhase 2 studyPhase II trialFollow-up timePre-clinical dataII clinical trialsPre-clinical evidenceImpaired homologous recombinationClinical Trials NetworkAdvanced chondrosarcomaMedian OSII trialIDH1/2 mutationsMedian age
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply